New Jersey is currently home to 1712 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Monitor Ambulatory Blood Pressure Monitoring in Hypogonadal Men Treated With Nasal Testosterone Gel
NCT04976595
Recruiting
The purpose of this study is to assess the change in 24-hour ambulatory blood pressure monitoring (ABPM) between baseline (Day 0) and Day 120 following 4 months of testosterone therapy with Natesto.
Gender:
Male
Ages:
Between 18 years and 80 years
Trial Updated:
07/04/2022
Locations: Premier Urology Group, Edison, New Jersey
Conditions: Hypogonadism
Register for Updates
Evaluation of the FELLAS Responsible Fatherhood Project
NCT05412641
Recruiting
The Partnership for Maternal and Child Health of Northern New Jersey, Inc. (PMCH) is implementing a fatherhood project with the goal of strengthening father-child engagement, improving economic stability, and improving healthy marriage/relationship skills among participants. FELLAS serves community-based fathers 18 years of age or older who reside in Essex County, New Jersey and have at least one child under the age of 24. The program model has three components: to improve responsible parenting... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
06/07/2022
Locations: Partnership for Maternal & Child Health of Northern New Jersey, Newark, New Jersey
Conditions: Responsible Fatherhood
Register for Updates
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
NCT04857359
Recruiting
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/18/2022
Locations: Cooper University Hospital, Camden, New Jersey
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Register for Updates
Cross-sectional Evaluation of the Subjective Performance and Satisfaction With Ponto Sound Processors
NCT05356221
Recruiting
The study is a non-interventional, observational, cross-sectional, study on users of Ponto sound processors. The purpose of this study is to evaluate subjectively assessed hearing performance and satisfaction with Oticon Medical's sound processors fitted with the Genie Medical fitting software.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/10/2022
Locations: Oticon Medical, Somerset, New Jersey
Conditions: Hearing Loss, Hearing Loss, Conductive, Hearing Loss, Unilateral
Register for Updates
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)
NCT04209543
Recruiting
This is a two-part study designed to evaluate the effect of Estetrol (E4) 15 or 20 mg, or placebo on the severity and frequency of vasomotor symptoms (VMS) (Efficacy Study Part) and the safety of E4 20 mg (Endometrial and General Safety Study Part)
Gender:
Female
Ages:
Between 40 years and 65 years
Trial Updated:
05/09/2022
Locations: Hassman Research Institute, Berlin, New Jersey
Conditions: Vasomotor Symptoms, Menopausal Symptoms
Register for Updates
KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF
NCT04640532
Recruiting
This study evaluates KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/05/2022
Locations: Columbia University Medical Center, Fort Lee, New Jersey
Conditions: Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis
Register for Updates
"The Efficacy of Exparel Versus a Multidrug Cocktail in Soft Tissue Tumors"
NCT05355597
Recruiting
The objective of this proposed project is to determine which local anesthetic is more efficacious for use in soft tissue tumors: Exparel (liposomal bupivacaine) or a cocktail of Ropivicaine, Epinepherine, Ketolorac and Clonidine. This study will examine patients' post-operative pain levels as well as their narcotic consumption after removal of a soft tissue tumor while hospitalized and then twice daily through postoperative day 14.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/27/2022
Locations: Morristown Medical Center, Morristown, New Jersey
Conditions: Musculoskeletal Diseases, Soft Tissue Mass
Register for Updates
Telerehabilitation Cognitive Impairments Following Chemotherapy Feasibility Study
NCT04972019
Recruiting
Develop a game-based upper-extremity motor and cognitive rehabilitation system using custom and adaptable virtual reality simulations on a wearable device enhanced with biosensors. Participants are stage II and stage III breast cancer survivors with lasting cognitive impairments following their first round of chemotherapy. They will be randomized 1:1 into an experimental group and a sham control group. Each group will train in the home for 8 weeks, during which they will perform up to 4 rehabil... Read More
Gender:
Female
Ages:
Between 20 years and 65 years
Trial Updated:
04/27/2022
Locations: Rutgers University Rober Wood Johnson Medical School, New Brunswick, New Jersey
Conditions: Cognitive Impairment, Mild
Register for Updates
Machine Learning Sepsis Alert Notification Using Clinical Data
NCT04005001
Recruiting
Machine learning is a powerful method to create clinical decision support (CDS) tools, when training labels reflect the desired alert behavior. In our Phase I work for this project, we developed HindSight, an encoding software that was designed to examine discharged patients' electronic health records (EHRs), identify clinicians' sepsis treatment decisions and patient outcomes, and pass those labeled outcomes and treatment decisions to an online algorithm for retraining of our machine-learning-b... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/27/2022
Locations: Cooper University Health Care, Camden, New Jersey
Conditions: Sepsis, Severe Sepsis, Septic Shock
Register for Updates
Telerehabilitation Alzheimer's Disease Feasibility (TADF)
NCT04732182
Recruiting
This is a pilot RCT with equal arms: experimental arm and (wait list) control arm. All participants will be in the early stage of Alzheimer's disease and on stable medication. They will all continue with this medication for their 6 months participation. Experimental group will add weekly training on the experimental device, 5 days a week for 8 weeks. Training will involve therapeutic games aimed primarily at the memory cognitive domain. All participants will receive weekly calls from clinical... Read More
Gender:
All
Ages:
Between 65 years and 85 years
Trial Updated:
04/26/2022
Locations: Rutgers, The State University of New Jersey, New Brunswick, New Jersey
Conditions: Alzheimer Disease, Healthy Aging
Register for Updates
A Prospective Study to Evaluate Robot Assisted Total Knee Replacement Outcomes
NCT03523897
Recruiting
This study aims to see if outcomes for patients that receive the traditional total knee replacement surgical technique are different than the outcomes for patients that receive robot-assisted total knee replacement. The outcomes we will be tracking include: Patients' self-reported awareness of their artificial joints during activities of daily living; Patient's self-reported pain, other symptoms, function in daily living, function in sport and recreation, and knee-related quality of life; Patie... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2022
Locations: Virtua Joint Replacement Institute, Voorhees, New Jersey
Conditions: Primary Osteoarthritis of Knee Nos
Register for Updates
Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy
NCT05116813
Recruiting
This open-label study is designed to assess the long-term safety and tolerability of dipraglurant in PD patients for up to 52 weeks (at doses of 150-300 mg per day) for patients that have completed an Addex sponsored double-blind clinical trial of dipraglurant.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
04/18/2022
Locations: Rutgers, the State University of New Jersey, New Brunswick, New Jersey
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Register for Updates